BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 18980046)

  • 1. Advances in the treatment of acne.
    Kimball AB
    J Reprod Med; 2008 Sep; 53(9 Suppl):742-52. PubMed ID: 18980046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. YAZ and the novel progestin drospirenone.
    Mishell DR
    J Reprod Med; 2008 Sep; 53(9 Suppl):721-8. PubMed ID: 18980044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen: a randomized controlled trial.
    Maloney JM; Dietze P; Watson D; Niknian M; Lee-Rugh S; Sampson-Landers C; Korner P
    Obstet Gynecol; 2008 Oct; 112(4):773-81. PubMed ID: 18827119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of moderate acne vulgaris using a combined oral contraceptive containing ethinylestradiol 20 μg plus drospirenone 3mg administered in a 24/4 regimen: a pooled analysis.
    Koltun W; Maloney JM; Marr J; Kunz M
    Eur J Obstet Gynecol Reprod Biol; 2011 Apr; 155(2):171-5. PubMed ID: 21288628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of 2 combined oral Contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea.
    van Vloten WA; van Haselen CW; van Zuuren EJ; Gerlinger C; Heithecker R
    Cutis; 2002 Apr; 69(4 Suppl):2-15. PubMed ID: 12096825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
    Cianci A; De Leo V
    Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hormonal contraceptives for acne management.
    Rich P
    Cutis; 2008 Jan; 81(1 Suppl):13-8. PubMed ID: 18338653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Should dermatologists prescribe hormonal contraceptives for acne?
    Harper JC
    Dermatol Ther; 2009; 22(5):452-7. PubMed ID: 19845722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral contraceptives in the treatment of acne.
    Tan JK; Degreef H
    Skin Therapy Lett; 2001 Feb; 6(5):1-3. PubMed ID: 11242137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality of life issues. Potential role for an oral contraceptive containing ethinyl estradiol and drospirenone.
    Dickerson V
    J Reprod Med; 2002 Nov; 47(11 Suppl):985-93. PubMed ID: 12497673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial.
    Koltun W; Lucky AW; Thiboutot D; Niknian M; Sampson-Landers C; Korner P; Marr J
    Contraception; 2008 Apr; 77(4):249-56. PubMed ID: 18342647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Extracontraceptive benefits of EE/DRSP (Yaz) in 24+4 day regimen].
    Bruni Bresciani V
    Minerva Ginecol; 2010 Jun; 62(3):261-6. PubMed ID: 20595950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerance of acne treatment using both spironolactone and a combined contraceptive containing drospirenone.
    Krunic A; Ciurea A; Scheman A
    J Am Acad Dermatol; 2008 Jan; 58(1):60-2. PubMed ID: 17964689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of a combined oral contraceptive containing 0.030 mg ethinylestradiol/2 mg dienogest for the treatment of papulopustular acne in comparison with placebo and 0.035 mg ethinylestradiol/2 mg cyproterone acetate.
    Palombo-Kinne E; Schellschmidt I; Schumacher U; Gräser T
    Contraception; 2009 Apr; 79(4):282-9. PubMed ID: 19272497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acne vulgaris: recent advances in pathogenesis and treatment.
    Caro I
    J Fam Pract; 1977 Nov; 5(5):747-50. PubMed ID: 144774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hormonal therapy for acne using oral contraceptive pills.
    Harper JC
    Semin Cutan Med Surg; 2005 Jun; 24(2):103-6. PubMed ID: 16092798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An oral contraceptive with 3 approved indications.
    Mishell DR
    J Reprod Med; 2008 Sep; 53(9 Suppl):717-9. PubMed ID: 18980043
    [No Abstract]   [Full Text] [Related]  

  • 18. Drospirenone/ethinylestradiol 3mg/20microg (24/4 day regimen): a review of its use in contraception, premenstrual dysphoric disorder and moderate acne vulgaris.
    Fenton C; Wellington K; Moen MD; Robinson DM
    Drugs; 2007; 67(12):1749-65. PubMed ID: 17683173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacologic modulation of sebaceous gland activity: mechanisms and clinical applications.
    Clarke SB; Nelson AM; George RE; Thiboutot DM
    Dermatol Clin; 2007 Apr; 25(2):137-46, v. PubMed ID: 17430751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution of progestins. Focus on the novel progestin drospirenone.
    Thorneycroft IH
    J Reprod Med; 2002 Nov; 47(11 Suppl):975-80. PubMed ID: 12497671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.